$IQV

BOUSBIB ARI sold (to issuer) $12.2M of IQV

BOUSBIB ARI (See Remarks) sold (to issuer) 49,927 shares of IQVIA HOLDINGS INC. (IQV) at an average of $244.70 ($244.60–$247.00, $12.22M total) across 2 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure provides a concrete insider activity datapoint (size, price range, and sale-to-issuer code) but does not introduce new fundamental information.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the filing does not change IQVIA’s outlook.

03

What to watch

No 10b5-1 plan is indicated, so traders may scrutinize whether the sale was discretionary versus plan-driven, though the filing still lacks any stated rationale.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31, transaction dated 2026-07-29

Background

SEC Form 4 insider transaction for IQVIA Holdings Inc., reported by officer/director BOUSBIB ARI.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold 49,927 shares to the issuer for about $12.22M at $244.60 to $247.00 on 2026-07-29.

Expected impact

Likely limited near-term impact; any effect is more about interpreting insider behavior than new fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with transaction size and pricing, but it does not include new company guidance, operating results, or regulatory/legal developments.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the code is sale to issuer, the transaction may reflect routine buyback participation or pre-arranged mechanics rather than a negative view on IQVIA.

Key entities

  • IQVIA HOLDINGS INC.

    Company whose insider transaction is disclosed on SEC Form 4.

  • BOUSBIB ARI

    Officer and director reporting the sale to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.